TeriparatidePTH fragment · osteoporosis medicine
Teriparatide is an active fragment of parathyroid hormone used in osteoporosis care. The pattern of exposure matters: intermittent signalling can favour bone formation in people at substantial fracture risk.
What is Teriparatide?
Teriparatide is the 1–34 fragment of parathyroid hormone, used in osteoporosis treatment. Its intermittent exposure differs from sustained hormone-replacement approaches.
How it works
Intermittent PTH-receptor stimulation promotes bone formation. Bone-density changes and fracture outcomes are separate ways to assess this effect.
Effects studied
Osteoporosis outcomes
A landmark study in women with previous vertebral fractures assessed new fractures and bone mineral density. 1
Evidence: Clinical research in a selected high-risk population; effects should not be generalised to all low-bone-density situations.
What does the evidence show?
Randomised osteoporosis fracture trial
The timing is part of the biology
Teriparatide contains the first 34 amino acids of parathyroid hormone. PTH can influence both bone formation and breakdown, but these effects depend on how the signal reaches the body. Intermittent exposure is used to stimulate bone-forming activity in osteoporosis treatment.
What the fracture study adds
The landmark trial retained here studied women with osteoporosis and previous vertebral fractures. It measured new fractures as well as bone mineral density. These clinical outcomes provide more direct evidence for treatment than a laboratory finding that bone cells respond to a peptide. 1
Why patient selection still matters
Someone with a previous fragility fracture faces a different starting risk from a healthy person hoping to strengthen bones. The potential absolute benefit changes with that risk. Treatment also fits into a longer plan: gains in bone need to be considered alongside the strategy after the bone-forming course ends.
Safety is connected to the hormone’s job
Calcium changes, dizziness and other adverse effects matter, and certain skeletal conditions affect suitability. The retained product information helps identify these issues but cannot replace current local prescribing information. Teriparatide treatment for osteoporosis and prolonged PTH replacement for hypoparathyroidism require separate clinical assessment. 2
Safety & status
Calcium changes and dizziness are relevant adverse effects. Product information specifies skeletal conditions and other circumstances affecting suitability. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Is teriparatide the whole PTH hormone?
No. It contains amino acids 1–34 of the larger hormone.
Is it equivalent to continuous PTH replacement?
No. Intermittent exposure for osteoporosis and sustained replacement in hypoparathyroidism have different treatment objectives.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.